Patents Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Serv
  • Patent number: 10869865
    Abstract: The invention provides methods of treating or preventing malaria comprising administering to an animal an effective amount of a compound of formula I: Q-Y—R1—R2??(I), wherein Q, Y, R1, and R2 are as described herein. Methods of inhibiting a plasmodial surface anion channel of a parasite in an animal are also provided. The invention also provides pharmaceutical compositions comprising a compound represented by formula I in combination with any one or more compounds represented by formulas II, V, and VI. Use of the pharmaceutical compositions for treating or preventing malaria or for inhibiting a plasmodial surface anion channel in animals including humans are also provided. Also provided by the invention are clag3 amino acid sequences and related nucleic acids, vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: December 22, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventor: Sanjay A. Desai
  • Patent number: 10830678
    Abstract: This disclosure provides IR700-molecule conjugates and methods of their use to remove (e.g., separate or isolate) a target from a sample in vivo or from a subject in vitro. It is shown herein that exposure of IR700 to near infrared (NIR) light removes a portion of IR700, changing it from a hydrophilic molecule, to one that is hydrophobic, resulting in aggregation of IR700 and anything bound to it. For example, the disclosed IR700-molecule conjugates and methods provide photo-controlled ways to control the pharmacokinetics of a drug in vivo, and can be used to remove undesired agents from environmental or food samples or to isolate target molecules in a laboratory.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: November 10, 2020
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV
    Inventors: Hisataka Kobayashi, Peter Choyke, Martin John Schnermann
  • Patent number: 10662464
    Abstract: Described herein are massively parallel sequencing methods for virus-derived therapeutics such as viral vaccines, including the PVS-RIPO vaccine. The methods allow for the determination of micro-heterogeneity and quantitation of low frequency sequence variants and in the case of PVS-RIPO, are expected to replace the monkey neurovirulence safety test (MNVT) and the mutant analysis by PCR and restriction enzyme cleavage (MAPREC) methods that are currently used to screen lots of RNA virus-derived therapeutics.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: May 26, 2020
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Serv, American International Biotechnology, LLC
    Inventors: Trevor Lane Broadt, Michael D. Harwich, William T. Budd, Gregory A. Meyers
  • Publication number: 20190298824
    Abstract: The present disclosure concerns chemical conjugates having structures satisfying Formula I and methods of making and using these chemical conjugates. Also described are immunomodulatory compositions comprising the chemical conjugates and methods of using the chemical conjugates and/or immunomodulatory compositions thereof to induce an immune response in a subject.
    Type: Application
    Filed: May 4, 2017
    Publication date: October 3, 2019
    Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Xiaoyuan Chen, Guizhi Zhu
  • Publication number: 20190254624
    Abstract: Imaging of internal structure of a patient, such as the prostate, is performed using ultrasound tomography by inserting a first ultrasound probe into the rectum of the patient, positioning a second ultrasound probe on an abdomen of the patient, and aligning the first and second ultrasound probes with one another to obtain acoustic information for reconstructing tomographic images of the internal structure. Light sources can also be shined to the tissue of interest, such as prostate say by a transurethral catheter thus making photoacoustic waves that can be received by the said TRUS or TRAB/TRPR transducers to reconstruct photoacoustic tomographic image of the tissue, as well.
    Type: Application
    Filed: June 8, 2017
    Publication date: August 22, 2019
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, The Johns Hopkins University
    Inventors: Bradford Wood, Reza Seifabadi, Fereshteh Aalamifar, Emad Boctor, Arman Rahmim
  • Publication number: 20190241596
    Abstract: The invention provides a compound of the formula: and a capture support of the formula: wherein R1, R2, R3, R6, A, B, D, E, J, K, Q, W, and Z are as defined herein. The invention also provides a method of purifying an oligonucleotide or an oligonucleotide analog composed of “b” nucleotides from a mixture comprising the oligonucleotide or oligonucleotide analog and at least one oligonucleotide or oligonucleotide analog composed of “a” nucleotides, wherein b?a, comprising use of the compound and the capture support.
    Type: Application
    Filed: June 28, 2017
    Publication date: August 8, 2019
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Serge L. Beaucage, Andrzej Grajkowski
  • Publication number: 20190225811
    Abstract: Embodiments of C4?-alkyl-ether heptamethine cyanine fluorophores according to general formula I, and pharmaceutically acceptable salts thereof, are disclosed. Methods of making and using the C4?-alkyl-ether heptamethine cyanine fluorophores also are disclosed.
    Type: Application
    Filed: April 3, 2019
    Publication date: July 25, 2019
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Martin John Schnermann, Roger Rauhauser Nani, James Blaine Shaum
  • Publication number: 20190201414
    Abstract: The present invention provides a method of preventing or treating a Mycobacterium tuberculosis (Mtb) infection in a mammal the method comprising administering to the mammal a first inhibitor, wherein the first inhibitor is an inhibitor of heme degradation and wherein the first inhibitor is a metal protoporphyrin, and administering to the mammal a second inhibitor, wherein the second inhibitor is an inhibitor of Mtb, wherein administration of the first and second inhibitors to the mammal prevents or treats Mtb infection in the mammal.
    Type: Application
    Filed: June 29, 2017
    Publication date: July 4, 2019
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Diego Luis Costa, Bruno Bezerril Andrade, Franklin Alan Sher
  • Publication number: 20190183889
    Abstract: The invention provides methods of treating or preventing malaria comprising administering to an animal an effective amount of a compound of formula I: Q-Y—R1—R2??(I), wherein Q, Y, R1, and R2 are as described herein. Methods of inhibiting a plasmodial surface anion channel of a parasite in an animal are also provided. The invention also provides pharmaceutical compositions comprising a compound represented by formula I in combination with any one or more compounds represented by formulas II, V, and VI. Use of the pharmaceutical compositions for treating or preventing malaria or for inhibiting a plasmodial surface anion channel in animals including humans are also provided. Also provided by the invention are clag3 amino acid sequences and related nucleic acids, vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions.
    Type: Application
    Filed: March 5, 2019
    Publication date: June 20, 2019
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventor: Sanjay A. Desai
  • Publication number: 20190175214
    Abstract: Prostate biopsy systems are provided that include a 3D ultrasound probe support configured to receive an ultrasound probe for transperineal imaging. One or more template grids can have a plurality of apertures extending therethrough to receive and guide a biopsy needle along a trajectory associated with respective apertures when the template grid is fixed to the support and the biopsy system is positioned in the perineal area of a patient. Patient-specific template grids can also be developed and produced. This system enables fully transperineal prostate biopsy (i.e. both imaging and needle placement are perineal) and eliminates the need for an external racking device for image fusion as well as needle tracking.
    Type: Application
    Filed: July 28, 2017
    Publication date: June 13, 2019
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Bradford Wood, Sheng Xu, Reza Seifabadi
  • Publication number: 20190178964
    Abstract: Multi-dimensional spectra associated with a specimen are reconstructed using lower dimensional spectra as constraints. For example, a two-dimensional spectrum associated with diffusivity and spin-lattice relaxation time is obtained using one-dimensional spectra associated with diffusivity and spin-lattice relaxation time, respectively, as constraints. Data for a full two dimensional spectrum are not acquired, leading to significantly reduced data acquisition times.
    Type: Application
    Filed: August 11, 2017
    Publication date: June 13, 2019
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Peter J. Basser, Dan H. Benjamini
  • Publication number: 20190169569
    Abstract: Provided herein are methods of producing an RPE cell population from a starting cell suspension, such as a single cell suspension, of pluripotent stem cells (PSCs). Such a method may comprise culturing the starting single cell suspension of PSCs in differentiation media to produce human RPE cells.
    Type: Application
    Filed: September 7, 2016
    Publication date: June 6, 2019
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, Cellular Dynamics International, Inc.
    Inventors: Kapil Bharti, Lucas Chase, Feng Xuezhu, Balendu Shekhar Jha
  • Publication number: 20190160028
    Abstract: Provided is a method of inhibiting viral replication, including contacting one or more cells that has been infected or contacted with a flavivirus with an effective amount of niclosamide, temoporfin, nitazoxanide, tizoxanide, erythrosin B, methylene blue. Contacting one or more cells that have been infected with a flavivirus may include administering the compound to a mammal, a human, or other subject. The flavivirus may be Dengue virus serotype 1, Dengue virus serotype 2, Dengue virus serotype 3, Dengue virus serotype 4, yellow fever virus, West Nile virus, Zika virus, Japanese encephalitis virus, tick-born encephalitis virus, Powassan virus, St. Louis encephalitis virus, or other flavivirus.
    Type: Application
    Filed: June 23, 2017
    Publication date: May 30, 2019
    Applicants: HEALTH RESEARCH, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV
    Inventors: Hongmin LI, Laura D. KRAMER, Zhong LI, Ruili HUANG, Menghang XIA
  • Publication number: 20190151466
    Abstract: Methods of treating cancer or reducing the incidence of relapse of a cancer in a subject comprising co-administration of Toll-like receptor (TLR) 4 ligand, such as an HMGN1 protein, and a TLR 7 or 8 ligand, and optionally an immune checkpoint inhibitor, to the subject in need of such therapy. The TLR4-mediated immune-stimulating effect is synergistically enhanced by ligands of TLR7 or 8, and the immune checkpoint inhibitor. Also described here is a nanoparticle delivery platform for the co-administration of the TLR 4 ligand and the TLR 7 or 8 ligand.
    Type: Application
    Filed: February 24, 2017
    Publication date: May 23, 2019
    Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Joost J. Oppenheim, De Yang, Zen Han, Joseph John Barchi, Michael Bustin
  • Publication number: 20190113489
    Abstract: The invention provides a method for detecting the presence of a type I pyrethroid in an object comprising the steps of (a) contacting the object with a solvent and an absorbent substrate, (b) separating the absorbent substrate from the object, (c) evaporating the solvent from the absorbent substrate, (d) treating the absorbent substrate with a solution comprising a nitrite salt in concentrated sulfuric acid, and (e) observing the absorbent substrate for a color change indicating the presence of the type I pyrethroid in the object. The invention also provides a kit for detecting the presence of the type I pyrethroid in an object.
    Type: Application
    Filed: June 10, 2016
    Publication date: April 18, 2019
    Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV
    Inventor: Michael D. Green
  • Patent number: 10228376
    Abstract: The present invention provides a panel of at least five clinical analyses or tests (using serum samples) to determine the risk of pediatric acute-onset neuropsychiatric syndrome (PANS) and/or pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) in an individual. These include enzyme linked immunosorbent assays (ELISAs) to measure antibody titers against neuronal antigens present in the brain; the neuronal antigens include lysoganglioside, tubulin, dopamine receptor D1, dopamine receptor D2, serotonin receptor 5HT2A, and serotonin receptor 5HT2C. Antibody titers against at least four of these neuronal antigens are required in the present methods; preferably antibody tiers against all of these neuronal antigens are measured. A final assay is used to quantify calcium/calmodulin-dependent protein kinase activity using a neuronal cell line.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: March 12, 2019
    Assignees: Moleculera Labs, Inc., The Board of Regents of the University of Oklahoma, The United States of America, As Represented by the Secretary, Department of Health and Human Serv
    Inventors: Phina Madeleine Cunningham, Craig David Shimasaki, Susan E. Swedo, Christine Kirvan
  • Publication number: 20190047932
    Abstract: Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I: wherein R1 to R5 and X1 to X5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.
    Type: Application
    Filed: August 21, 2018
    Publication date: February 14, 2019
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Jane B. Neckers, Yeong Sang Kim, Sunmin Lee, Vineet Kumar, Sanjay V. Malhotra
  • Publication number: 20190046619
    Abstract: Brachyury protein can be used to induce Brachyury-specific CD4+ T cells in vivo and ex vivo. It is also disclosed that Brachyury protein can be used to stimulate the production of both Brachyury-specific CD4+ T cells and Brachyury-specific CD8+ T cells in a subject, such as a subject with cancer. In some embodiments, the methods include the administration of a Brachyury protein. In additional embodiments, the methods include the administration of a nucleic acid encoding the Brachyury protein, such as in a non-pox non-yeast vector. In further embodiments, the method include the administration of host cells expressing the Brachyury protein.
    Type: Application
    Filed: August 21, 2018
    Publication date: February 14, 2019
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Jeffrey Schlom, Claudia M. Palena
  • Publication number: 20190038627
    Abstract: Adenosine kinase inhibitors, including pharmaceutical compositions containing the adenosine kinase inhibitors, and their use for preventing epilepsy and its progression in patients. The adenosine kinase inhibitors have the formula: where the moieties J and K, considered in combination, are —CH2—, or K and L, considered in combination, are —CH2—. The R1 moiety can be —NH2, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 hydroxyalkyl. The R2 and R3 moieties are each independently C1-C6 alkyl. The R4 moiety is hydrogen or C1-C6 alkyl. The R5 and R6 moieties are each independently C6-C12 aryl, C3-C8 cycloalkyl, or C3-C8 heteroaryl, that is optionally further substituted.
    Type: Application
    Filed: July 9, 2018
    Publication date: February 7, 2019
    Applicants: Legacy Emanuel Hospital & Health Center, The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Kenneth Alan Jacobson, Detlev Boison, Kiran Shambhu Toti
  • Publication number: 20190016786
    Abstract: Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.
    Type: Application
    Filed: July 24, 2018
    Publication date: January 17, 2019
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Peter D. Kwong, Gary J. Nabel, Rebecca S. Rudicell, John Mascola, Mark Connors, Ivelin Georgiev, Jiang Zhu, Young Do Kwon, Tongqing Zhou, Yongping Yang, Baoshan Zhang, Gwo-Yu Chuang, Xueling Wu, Zhi-yong Yang, Wei Shi